新闻源 财富源

2019年10月16日 星期三

康缘药业(600557)公告正文

康缘药业:2017年第一季度报告

公告日期:2017-04-28

   江苏康缘药业股份有限公司 (股票代码:600557)              2017 年第一季度报告



公司代码:600557                                         公司简称:康缘药业




                 江苏康缘药业股份有限公司

                        2017 年第一季度报告




                                二〇一七年四月二十七日



                                            1 / 19
       江苏康缘药业股份有限公司 (股票代码:600557)                    2017 年第一季度报告




                                             目录
一、            重要提示 .............................................................. 3

二、            公司主要财务数据和股东变化 ............................................ 3

三、            重要事项 .............................................................. 5

四、            附录.................................................................. 8




                                                2 / 19
     江苏康缘药业股份有限公司 (股票代码:600557)                             2017 年第一季度报告




 一、      重要提示

 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,

 不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。

 1.2 公司全体董事出席董事会审议季度报告。

 1.3 公司负责人肖伟、主管会计工作负责人尹洪刚及会计机构负责人(会计主管人员)江锁成保

 证季度报告中财务报表的真实、准确、完整。

 1.4 本公司第一季度报告未经审计。


 二、      公司主要财务数据和股东变化

 2.1 主要财务数据

                                                                        单位:元 币种:人民币
                                                                             本报告期末比上年度
                                    本报告期末             上年度末
                                                                                 末增减(%)
总资产                           4,909,002,489.41      4,730,105,366.89                      3.78
归属于上市公司股东的净资产       3,230,145,205.64      3,143,302,504.20                      2.76
                                  年初至报告期末       上年初至上年报告
                                                                             比上年同期增减(%)
                                    (1-3 月)           期末(1-3 月)
经营活动产生的现金流量净额            9,739,697.39       137,589,323.00                    -92.92
                                  年初至报告期末       上年初至上年报告
                                                                             比上年同期增减(%)
                                    (1-3 月)           期末(1-3 月)
营业收入                            769,185,721.04       698,297,664.70                     10.15
归属于上市公司股东的净利润           86,844,327.44        82,365,842.77                      5.44
归属于上市公司股东的扣除非
                                     82,835,934.43        80,065,470.38                      3.46
经常性损益的净利润
加权平均净资产收益率(%)                       2.73                  2.89    减少 0.16 个百分点
基本每股收益(元/股)                           0.14                  0.13                   7.69
稀释每股收益(元/股)                           0.14                  0.13                   7.69

     公司主要会计数据和财务指标的说明

     公司于 2016 年 6 月实施完成 2015 年度利润分配方案,总股本由 513,707,601 股变为
 616,449,121 股,根据《企业会计准则第 34 号—每股收益》应用指南的规定,本公司按照调整后
 的 616,449,121 股重新计算列报期间的每股收益。

 非经常性损益项目和金额
 √适用 □不适用
                                                                        单位:元 币种:人民币

                                              3 / 19
       江苏康缘药业股份有限公司 (股票代码:600557)                                   2017 年第一季度报告



                                 项目                                                  本期金额
 非流动资产处置损益                                                                             -54,064.66
 计入当期损益的政府补助,但与公司正常经营业务密切相关,符合
                                                                                           4,748,485.89
 国家政策规定、按照一定标准定额或定量持续享受的政府补助除外
 除上述各项之外的其他营业外收入和支出                                                           147,463.28
 其他符合非经常性损益定义的损益项目
 少数股东权益影响额(税后)                                                                     -82,115.75
 所得税影响额                                                                                -751,375.75
                                 合计                                                      4,008,393.01


 2.2 截止报告期末的股东总数、前十名股东、前十名流通股东(或无限售条件股东)持股情况表

                                                                                                  单位:股
股东总数(户)                                                                                        30,258
                                          前十名股东持股情况
                                                              持有有限售
                                      期末持股      比例                    质押或冻结情况
         股东名称(全称)                                     条件股份数                           股东性质
                                         数量          (%)
                                                                  量        股份状态     数量
                                                                                                  境内非国有
江苏康缘集团有限责任公司             169,416,462    27.48     162,269,684      无            0
                                                                                                     法人
                                                                                                  境内非国有
连云港康贝尔医疗器械有限公司          31,870,567       5.17            0       无            0
                                                                                                     法人
中央汇金资产管理有限责任公司          18,280,080       2.97            0       无            0       其他
肖伟                                  17,003,232       2.76            0       无            0    境内自然人
汇添富基金-工商银行-汇添富-康
                                      11,945,196       1.94            0       无            0       其他
缘资产管理计划
中国工商银行股份有限公司-东方红
中国优势灵活配置混合型证券投资基      11,509,991       1.87            0       无            0       其他

东方证券股份有限公司                    6,068,719      0.98            0       无            0       其他
中国农业银行股份有限公司-博时裕
                                        6,053,245      0.98            0       无            0       其他
隆灵活配置混合型证券投资基金
博时基金-农业银行-博时中证金融
                                        5,439,480      0.88            0       无            0       其他
资产管理计划
易方达基金-农业银行-易方达中证
                                        5,439,480      0.88            0       无            0       其他
金融资产管理计划
大成基金-农业银行-大成中证金融
                                        5,439,480      0.88            0       无            0       其他
资产管理计划
嘉实基金-农业银行-嘉实中证金融
                                        5,439,480      0.88            0       无            0       其他
资产管理计划
中欧基金-农业银行-中欧中证金融
                                        5,439,480      0.88            0       无            0       其他
资产管理计划
工银瑞信基金-农业银行-工银瑞信
                                        5,439,480      0.88            0       无            0       其他
中证金融资产管理计划
                                     前十名无限售条件股东持股情况
                    股东名称                        持有无限售条件流                股份种类及数量

                                                 4 / 19
          江苏康缘药业股份有限公司 (股票代码:600557)                                 2017 年第一季度报告



                                                          通股的数量             种类               数量
 连云港康贝尔医疗器械有限公司                                31,870,567      人民币普通股         31,870,567
 中央汇金资产管理有限责任公司                                18,280,080      人民币普通股         18,280,080
 肖伟                                                        17,003,232      人民币普通股         17,003,232
 中国工商银行股份有限公司-东方红中国优势灵活配
                                                             11,509,991      人民币普通股         11,509,991
 置混合型证券投资基金
 江苏康缘集团有限责任公司                                     7,146,778      人民币普通股           7,146,778
 东方证券股份有限公司                                         6,068,719      人民币普通股           6,068,719
 中国农业银行股份有限公司-博时裕隆灵活配置混合
                                                              6,053,245      人民币普通股           6,053,245
 型证券投资基金
 博时基金-农业银行-博时中证金融资产管理计划                 5,439,480      人民币普通股           5,439,480
 易方达基金-农业银行-易方达中证金融资产管理计
                                                              5,439,480      人民币普通股           5,439,480
 划
 大成基金-农业银行-大成中证金融资产管理计划                 5,439,480      人民币普通股           5,439,480
 嘉实基金-农业银行-嘉实中证金融资产管理计划                 5,439,480      人民币普通股           5,439,480
 中欧基金-农业银行-中欧中证金融资产管理计划                 5,439,480      人民币普通股           5,439,480
 工银瑞信基金-农业银行-工银瑞信中证金融资产管
                                                              5,439,480      人民币普通股           5,439,480
 理计划
                                                      前十大股东中,江苏康缘集团有限责任公司、汇添富基金
                                                      -工商银行-汇添富-康缘资产管理计划和肖伟先生为一
                                                      致行动人。公司未知其他股东之间、其他股东与前十名无
 上述股东关联关系或一致行动的说明
                                                      限售条件股东之间是否存在关联关系或一致行动人关系;
                                                      公司未知其他前十名无限售条件股东之间是否存在关联关
                                                      系或一致行动人关系。



  2.3 截止报告期末的优先股股东总数、前十名优先股股东、前十名优先股无限售条件股东持股情
      况表

  □适用 √不适用

  三、        重要事项

  3.1 公司主要会计报表项目、财务指标重大变动的情况及原因

  √适用 □不适用

         3.1.1 截至报告期末,公司资产负债表项目大幅变动的原因分析

                                                                             单位:元       币种:人民币
                                                              变动比例
      项目名称          本期期末数         本期期初数                                    情况说明
                                                                (%)
                                                                             主要系本期支付南京华泰大健
货币资金              139,723,929.52     248,391,832.33          -43.75      康资金 2500 万元与中核新能源
                                                                             股权投资款 1 亿元所致
                                                                             主要系本期认购南京华泰大健
可供出售金融资
                      145,748,439.62      20,654,100.00          605.66      康与中核新能源股权投资份额

                                                                             所致


                                                   5 / 19
       江苏康缘药业股份有限公司 (股票代码:600557)                          2017 年第一季度报告


                                                                     主要系本期控股子公司德福康
在建工程            25,002,183.64      16,254,741.31         53.81
                                                                     缘增加技术改造工程所致
                                                                     主要系本期贴现利率较高调整
短期借款           339,880,102.31     229,880,102.31         47.85
                                                                     融资结构所致
预收款项            31,657,855.50      45,477,324.72        -30.39   主要系本期预收款转货款所致
                                                                     主要系按照权责发生制计提的
应付职工薪酬         3,384,577.53       7,411,951.13        -54.34
                                                                     年终奖金在本期支付所致
                                                                     主要系到期还本付息的超短期
应付利息             6,929,466.47       4,386,268.75         57.98
                                                                     融资券计提应付利息所致

一年内到期的非                                                       主要系报告期内偿还一年内到
                              0.00     45,000,000.00       -100.00
流动负债                                                             期的非流动负债所致
                                                                     主要系本期增加控股子公司康
少数股东权益        95,574,655.21      62,515,628.01         52.88
                                                                     缘华威少数股东权益所致

    3.1.2 截至报告期末,公司利润表项目大幅变动的原因分析

                                                                        单位:元     币种:人民币
                                          去年同期       变动比例
   项目名称            本期金额                                                情况说明
                                            金额           (%)
                                                                     主要系公司根据 2016 年 12 月份
                                                                     财会[2016]22 号文关于印发《增
                                                                     值税会计处理规定》的通知中相
税金及附加           15,438,957.16     11,442,302.03         34.93
                                                                     关规定,将房产税、土地使用税
                                                                     等四小税由管理费用转入税金
                                                                     及附加所致
                                                                     主要系本期政府补助确认为营
营业外收入             4,846,785.42     2,759,658.37         75.63   业外收入金额较去年同期增加
                                                                     所致

    3.1.3 截至报告期末,公司现金流量表项目大幅变动的原因分析

                                                                         单位:元 币种:人民币
                                         去年同期        变动比例
   项目名称           本期金额                                                 情况说明
                                           金额            (%)
                                                                     主要系本期票据贴现减少导致
经营活动产生的
                     9,739,697.39     137,589,323.00        -92.92   所确认的销售商品、提供劳务收
现金流量净额
                                                                     到的现金减少所致
筹资活动产生的                                                       主要系本期票据贴现利率较高
                    82,066,856.13      28,045,311.19        192.62
现金流量净额                                                         调整融资结构所致


  3.2 重要事项进展情况及其影响和解决方案的分析说明

  √适用 □不适用

      1、关于认购华泰大健康股权投资基金份额的说明


                                                6 / 19
    江苏康缘药业股份有限公司 (股票代码:600557)                          2017 年第一季度报告



    2016年9月5日经公司第六届董事会第一次会议审议通过《关于拟认购华泰大健康股权投资基
金份额的议案》,同意公司以自有资金 5,000 万元认购华泰证券股份有限公司拟设立并发行的华
泰大健康股权投资基金份额。(详见2016年9月6日刊登于海证券交易所网站 www.sse.com.cn、《中
国证券报》、《上海证券报》公告,公告编号:2016-028。)

    2017年1月,公司已按合同约定支付2,500万元。该基金的认购除预计能为公司获得财务投资
收益外,还可以提供优质资源,获取更多的产业整合和并购重组的条件和机会,推进公司对外投
资和外延拓展战略目标实现。

    2、关于投资中核新能源投资有限公司增资扩股的说明

    2017年1月,公司与中核新能源投资有限公司(以下简称“中核新能源”)签署增资扩股协议,
以1亿元人民币投资中核新能源,投资款已于2017年1月支付完毕,投资后公司持有中核新能源股
权的比例为5.55%。

    中核新能源增资扩股后的注册资本为92,861.68万人民币,中核新能源目前以生活污水投资建
设运营为主业,系中国核工业建设集团公司旗下企业,主要股东为中国核建集团旗下的中核投资
有限公司和中国核工业华兴建设有限公司。


3.3 报告期内超期未履行完毕的承诺事项

□适用 √不适用


3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大变动的
    警示及原因说明

□适用 √不适用




                                                      公司名称     江苏康缘药业股份有限公司
                                                      法定代表人   肖伟

                                                      日期         2017 年 4 月 27 日




                                             7 / 19
    江苏康缘药业股份有限公司 (股票代码:600557)                          2017 年第一季度报告



四、 附录

4.1 财务报表

                                        合并资产负债表
                                       2017 年 3 月 31 日
编制单位:江苏康缘药业股份有限公司
                                                    单位:元 币种:人民币 审计类型:未经审计
               项目                                 期末余额               年初余额
流动资产:
    货币资金                                         139,723,929.52          248,391,832.33
    结算备付金
    拆出资金
    以公允价值计量且其变动计入当
期损益的金融资产
    衍生金融资产
    应收票据                                      789,886,105.29             842,683,359.01
    应收账款                                    1,190,494,570.41             975,742,050.02
    预付款项                                       22,777,190.91              27,144,343.36
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息
    应收股利
    其他应收款                                        45,126,228.00           51,116,716.79
    买入返售金融资产
    存货                                             206,058,396.56          192,236,251.39
    划分为持有待售的资产
    一年内到期的非流动资产
    其他流动资产                                    7,319,720.81               6,310,053.32
      流动资产合计                              2,401,386,141.50           2,343,624,606.22
非流动资产:
    发放贷款和垫款
    可供出售金融资产                                 145,748,439.62           20,654,100.00
    持有至到期投资
    长期应收款
    长期股权投资                                       3,979,953.99            3,979,953.99
    投资性房地产
    固定资产                                    1,860,259,326.54           1,861,957,567.72
    在建工程                                       25,002,183.64              16,254,741.31
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                         307,713,329.57          314,356,799.04
    开发支出                                          69,585,000.00           69,585,000.00
    商誉                                              58,988,858.14           58,988,858.14
                                             8 / 19
    江苏康缘药业股份有限公司 (股票代码:600557)                     2017 年第一季度报告



    长期待摊费用                                    5,837,760.30          6,637,684.71
    递延所得税资产                                  8,854,210.45          9,174,167.05
    其他非流动资产                                 21,647,285.66         24,891,888.71
      非流动资产合计                            2,507,616,347.91      2,386,480,760.67
        资产总计                                4,909,002,489.41      4,730,105,366.89
流动负债:
    短期借款                                        339,880,102.31      229,880,102.31
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    以公允价值计量且其变动计入当
期损益的金融负债
    衍生金融负债
    应付票据
    应付账款                                        293,616,316.82      255,858,276.28
    预收款项                                         31,657,855.50       45,477,324.72
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                                      3,384,577.53        7,411,951.13
    应交税费                                         85,066,843.59       72,528,826.68
    应付利息                                          6,929,466.47        4,386,268.75
    应付股利                                              8,437.50            8,437.50
    其他应付款                                      438,841,637.72      478,867,332.70
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    划分为持有待售的负债
    一年内到期的非流动负债                                               45,000,000.00
    其他流动负债                                  300,000,000.00        300,000,000.00
      流动负债合计                              1,499,385,237.44      1,439,418,520.07
非流动负债:
    长期借款
    应付债券
    其中:优先股
          永续债
    长期应付款
    长期应付职工薪酬
    专项应付款                                         2,139,581.00       2,139,581.00
    预计负债
    递延收益                                          81,757,810.12      82,729,133.61
    递延所得税负债
    其他非流动负债
      非流动负债合计                               83,897,391.12         84,868,714.61
        负债合计                                1,583,282,628.56      1,524,287,234.68
所有者权益

                                             9 / 19
    江苏康缘药业股份有限公司 (股票代码:600557)                        2017 年第一季度报告



    股本                                            616,449,121.00         616,449,121.00
    其他权益工具
    其中:优先股
           永续债
    资本公积                                        520,433,141.68         520,433,141.68
    减:库存股
    其他综合收益                                       -199,068.15             -197,442.15
    专项储备
    盈余公积                                        274,769,005.39         274,769,005.39
    一般风险准备
    未分配利润                                  1,818,693,005.72         1,731,848,678.28
    归属于母公司所有者权益合计                  3,230,145,205.64         3,143,302,504.20
    少数股东权益                                   95,574,655.21            62,515,628.01
      所有者权益合计                            3,325,719,860.85         3,205,818,132.21
         负债和所有者权益总计                   4,909,002,489.41         4,730,105,366.89



法定代表人:肖伟              主管会计工作负责人:尹洪刚             会计机构负责人:江锁成




                                            10 / 19
    江苏康缘药业股份有限公司 (股票代码:600557)                         2017 年第一季度报告



                                      母公司资产负债表
                                      2017 年 3 月 31 日
编制单位:江苏康缘药业股份有限公司
                                                    单位:元 币种:人民币 审计类型:未经审计
                 项目                                期末余额              年初余额
流动资产:
  货币资金                                             62,260,322.83        177,630,964.85
  以公允价值计量且其变动计入当期损
益的金融资产
  衍生金融资产
  应收票据                                            682,328,843.69        678,178,494.83
  应收账款                                          1,141,322,188.69        933,037,857.24
  预付款项                                             30,106,416.10         24,372,365.48
  应收利息
  应收股利                                              4,759,107.34          4,759,107.34
  其他应收款                                          278,224,259.91        342,803,176.92
  存货                                                180,580,102.66        166,681,188.15
  划分为持有待售的资产
  一年内到期的非流动资产
  其他流动资产
    流动资产合计                                    2,379,581,241.22      2,327,463,154.81
非流动资产:
  可供出售金融资产                                    145,748,439.62         20,654,100.00
  持有至到期投资
  长期应收款
  长期股权投资                                        252,534,036.66        204,534,036.66
  投资性房地产
  固定资产                                          1,574,307,084.95      1,572,267,274.26
  在建工程                                             13,995,484.53         11,266,315.06
  工程物资
  固定资产清理
  生产性生物资产
  油气资产
  无形资产                                            244,007,020.66        249,568,164.22
  开发支出                                             18,000,000.00         18,000,000.00
  商誉
  长期待摊费用                                          5,194,853.57          5,934,505.49
  递延所得税资产                                        3,991,292.10          3,864,098.62
  其他非流动资产                                       19,448,967.89         19,343,532.74
    非流动资产合计                                  2,277,227,179.98      2,105,432,027.05
      资产总计                                      4,656,808,421.20      4,432,895,181.86
流动负债:
  短期借款                                            339,880,102.31        229,880,102.31
  以公允价值计量且其变动计入当期损
益的金融负债
  衍生金融负债

                                            11 / 19
    江苏康缘药业股份有限公司 (股票代码:600557)                          2017 年第一季度报告



  应付票据
  应付账款                                            244,496,563.52         168,130,866.84
  预收款项                                             22,432,180.64          25,155,798.56
  应付职工薪酬                                            433,546.00           4,248,741.78
  应交税费                                             73,549,855.48          58,058,800.54
  应付利息                                              6,929,466.47           4,386,268.75
  应付股利
  其他应付款                                          415,780,887.48         429,304,944.60
  划分为持有待售的负债
  一年内到期的非流动负债                                                      45,000,000.00
  其他流动负债                                        300,000,000.00         300,000,000.00
    流动负债合计                                    1,403,502,601.90       1,264,165,523.38
非流动负债:
  长期借款
  应付债券
  其中:优先股
        永续债
  长期应付款
  长期应付职工薪酬
  专项应付款                                            2,139,581.00           2,139,581.00
  预计负债
  递延收益                                             59,209,126.52          60,056,183.51
  递延所得税负债
  其他非流动负债
    非流动负债合计                                     61,348,707.52          62,195,764.51
      负债合计                                      1,464,851,309.42       1,326,361,287.89
所有者权益:
  股本                                                616,449,121.00         616,449,121.00
  其他权益工具
  其中:优先股
        永续债
  资本公积                                            520,570,073.21         520,570,073.21
  减:库存股
  其他综合收益
  专项储备
  盈余公积                                            272,961,844.83         272,961,844.83
  未分配利润                                        1,781,976,072.74       1,696,552,854.93
    所有者权益合计                                  3,191,957,111.78       3,106,533,893.97
      负债和所有者权益总计                          4,656,808,421.20       4,432,895,181.86



法定代表人:肖伟              主管会计工作负责人:尹洪刚               会计机构负责人:江锁成




                                            12 / 19
    江苏康缘药业股份有限公司 (股票代码:600557)                           2017 年第一季度报告



                                          合并利润表
                                        2017 年 1—3 月
编制单位:江苏康缘药业股份有限公司
                                                    单位:元 币种:人民币 审计类型:未经审计
                    项目                            本期金额(1-3 月)    上期金额(1-3 月)
一、营业总收入                                          769,185,721.04        698,297,664.70
其中:营业收入                                          769,185,721.04        698,297,664.70
      利息收入
      已赚保费
      手续费及佣金收入
二、营业总成本                                          669,903,170.15        602,942,963.61
其中:营业成本                                          196,873,078.83        192,270,597.44
      利息支出
      手续费及佣金支出
      退保金
      赔付支出净额
      提取保险合同准备金净额
      保单红利支出
      分保费用
      营业税金及附加                                     15,438,957.16         11,442,302.03
      销售费用                                          336,496,639.08        286,966,927.63
      管理费用                                          110,768,607.65         99,115,343.10
      财务费用                                           10,793,751.46         12,858,600.98
      资产减值损失                                         -467,864.03            289,192.43
  加:公允价值变动收益(损失以“-”号填
列)
      投资收益(损失以“-”号填列)
      其中:对联营企业和合营企业的投资收

      汇兑收益(损失以“-”号填列)
三、营业利润(亏损以“-”号填列)                        99,282,550.89        95,354,701.09
  加:营业外收入                                           4,846,785.42         2,759,658.37
      其中:非流动资产处置利得
  减:营业外支出                                              95,100.91             35,973.46
      其中:非流动资产处置损失
四、利润总额(亏损总额以“-”号填列)                  104,034,235.40         98,078,386.00
  减:所得税费用                                         16,130,880.76         15,155,903.08
五、净利润(净亏损以“-”号填列)                       87,903,354.64         82,922,482.92
  归属于母公司所有者的净利润                             86,844,327.44         82,365,842.77
  少数股东损益                                            1,059,027.20            556,640.15
六、其他综合收益的税后净额                                   -1,626.00             -1,709.32
  归属母公司所有者的其他综合收益的税后净
                                                              -1,626.00             -1,709.32

    (一)以后不能重分类进损益的其他综合
收益
      1.重新计量设定受益计划净负债或净资

                                            13 / 19
    江苏康缘药业股份有限公司 (股票代码:600557)                           2017 年第一季度报告



产的变动
      2.权益法下在被投资单位不能重分类进
损益的其他综合收益中享有的份额
    (二)以后将重分类进损益的其他综合收
                                                           -1,626.00                -1,709.32

      1.权益法下在被投资单位以后将重分类
进损益的其他综合收益中享有的份额
      2.可供出售金融资产公允价值变动损益
      3.持有至到期投资重分类为可供出售金
融资产损益
      4.现金流量套期损益的有效部分
      5.外币财务报表折算差额                               -1,626.00                -1,709.32
      6.其他
  归属于少数股东的其他综合收益的税后净额
七、综合收益总额                                      87,901,728.64            82,920,773.60
  归属于母公司所有者的综合收益总额                    86,842,701.44            82,364,133.45
  归属于少数股东的综合收益总额                         1,059,027.20               556,640.15
八、每股收益:
  (一)基本每股收益(元/股)                                    0.14                       0.13
  (二)稀释每股收益(元/股)                                    0.14                       0.13



法定代表人:肖伟              主管会计工作负责人:尹洪刚               会计机构负责人:江锁成




                                            14 / 19
    江苏康缘药业股份有限公司 (股票代码:600557)                           2017 年第一季度报告



                                         母公司利润表
                                        2017 年 1—3 月
编制单位:江苏康缘药业股份有限公司
                                                单位:元 币种:人民币 审计类型:未经审计
                   项目                           本期金额(1-3 月)  上期金额(1-3 月)
一、营业收入                                          667,436,041.89      595,734,024.24
  减:营业成本                                        175,252,163.95      168,321,654.36
       营业税金及附加                                   13,567,746.38        9,749,506.92
       销售费用                                       275,995,438.59      225,653,555.37
       管理费用                                         96,952,996.55       86,825,634.37
       财务费用                                          8,728,363.12        9,364,338.64
       资产减值损失                                        847,956.51     -12,861,337.83
  加:公允价值变动收益(损失以“-”号填
列)
       投资收益(损失以“-”号填列)
       其中:对联营企业和合营企业的投资收

二、营业利润(亏损以“-”号填列)                        96,091,376.79       108,680,672.41
  加:营业外收入                                           4,416,526.52         2,704,000.00
       其中:非流动资产处置利得
  减:营业外支出                                              10,000.00             17,221.57
       其中:非流动资产处置损失
三、利润总额(亏损总额以“-”号填列)                100,497,903.31          111,367,450.84
    减:所得税费用                                     15,074,685.50           16,705,117.63
四、净利润(净亏损以“-”号填列)                     85,423,217.81           94,662,333.21
五、其他综合收益的税后净额
  (一)以后不能重分类进损益的其他综合收

     1.重新计量设定受益计划净负债或净资产
的变动
    2.权益法下在被投资单位不能重分类进损
益的其他综合收益中享有的份额
  (二)以后将重分类进损益的其他综合收益
     1.权益法下在被投资单位以后将重分类进
损益的其他综合收益中享有的份额
     2.可供出售金融资产公允价值变动损益
     3.持有至到期投资重分类为可供出售金融
资产损益
     4.现金流量套期损益的有效部分
     5.外币财务报表折算差额
     6.其他
六、综合收益总额                                          85,423,217.81        94,662,333.21
七、每股收益:
    (一)基本每股收益(元/股)
    (二)稀释每股收益(元/股)

法定代表人:肖伟             主管会计工作负责人:尹洪刚               会计机构负责人:江锁成
                                            15 / 19
    江苏康缘药业股份有限公司 (股票代码:600557)                         2017 年第一季度报告



                                        合并现金流量表
                                        2017 年 1—3 月
编制单位:江苏康缘药业股份有限公司
                                                单位:元 币种:人民币 审计类型:未经审计
                项目                          本期金额(1-3月)        上期金额(1-3月)
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金                        706,510,056.43        880,423,300.58
  客户存款和同业存放款项净增加额
  向中央银行借款净增加额
  向其他金融机构拆入资金净增加额
  收到原保险合同保费取得的现金
  收到再保险业务现金净额
  保户储金及投资款净增加额
  处置以公允价值计量且其变动计入当
期损益的金融资产净增加额
  收取利息、手续费及佣金的现金
  拆入资金净增加额
  回购业务资金净增加额
  收到的税费返还
  收到其他与经营活动有关的现金                         32,937,664.85         47,036,538.54
    经营活动现金流入小计                              739,447,721.28        927,459,839.12
  购买商品、接受劳务支付的现金                         92,405,674.07        232,383,724.91
  客户贷款及垫款净增加额
  存放中央银行和同业款项净增加额
  支付原保险合同赔付款项的现金
  支付利息、手续费及佣金的现金
  支付保单红利的现金
  支付给职工以及为职工支付的现金                      101,696,761.45         91,983,261.54
  支付的各项税费                                      128,365,275.12        127,229,612.25
  支付其他与经营活动有关的现金                        407,240,313.25        338,273,917.42
    经营活动现金流出小计                              729,708,023.89        789,870,516.12
      经营活动产生的现金流量净额                        9,739,697.39        137,589,323.00
二、投资活动产生的现金流量:
  收回投资收到的现金
  取得投资收益收到的现金
  处置固定资产、无形资产和其他长期资
                                                           40,400.00               1,270.00
产收回的现金净额
  处置子公司及其他营业单位收到的现
金净额
  收到其他与投资活动有关的现金
    投资活动现金流入小计                                  40,400.00                1,270.00
  购建固定资产、无形资产和其他长期资
                                                       75,513,677.95        173,088,698.40
产支付的现金
  投资支付的现金                                      125,000,000.00          4,650,000.00
  质押贷款净增加额
  取得子公司及其他营业单位支付的现

                                            16 / 19
    江苏康缘药业股份有限公司 (股票代码:600557)                            2017 年第一季度报告



金净额
  支付其他与投资活动有关的现金
    投资活动现金流出小计                             200,513,677.95            177,738,698.40
      投资活动产生的现金流量净额                    -200,473,277.95           -177,737,428.40
三、筹资活动产生的现金流量:
  吸收投资收到的现金                                   32,000,000.00
  其中:子公司吸收少数股东投资收到的
现金
  取得借款收到的现金                                  503,000,000.00           686,000,000.00
  发行债券收到的现金
  收到其他与筹资活动有关的现金
    筹资活动现金流入小计                              535,000,000.00           686,000,000.00
  偿还债务支付的现金                                  448,000,000.00           651,195,693.98
  分配股利、利润或偿付利息支付的现金                    4,933,143.87             6,758,994.83
  其中:子公司支付给少数股东的股利、
利润
  支付其他与筹资活动有关的现金
    筹资活动现金流出小计                             452,933,143.87            657,954,688.81
      筹资活动产生的现金流量净额                      82,066,856.13             28,045,311.19
四、汇率变动对现金及现金等价物的影响                      -1,178.38                 -1,204.47
五、现金及现金等价物净增加额                        -108,667,902.81            -12,103,998.68
  加:期初现金及现金等价物余额                       248,391,832.33            221,716,287.08
六、期末现金及现金等价物余额                         139,723,929.52            209,612,288.40



法定代表人:肖伟              主管会计工作负责人:尹洪刚               会计机构负责人:江锁成




                                            17 / 19
    江苏康缘药业股份有限公司 (股票代码:600557)                         2017 年第一季度报告



                                  母公司现金流量表
                                    2017 年 1—3 月
编制单位:江苏康缘药业股份有限公司
                                            单位:元 币种:人民币 审计类型:未经审计
                项目                          本期金额(1-3月)        上期金额(1-3月)
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金                        577,651,252.95        773,207,471.07
  收到的税费返还
  收到其他与经营活动有关的现金                        125,911,178.62         18,213,486.19
    经营活动现金流入小计                              703,562,431.57        791,420,957.26
  购买商品、接受劳务支付的现金                         79,954,040.29        212,208,828.39
  支付给职工以及为职工支付的现金                       85,370,487.81         73,807,475.39
  支付的各项税费                                      110,980,642.64        108,275,709.54
  支付其他与经营活动有关的现金                        378,706,415.84        289,483,242.07
    经营活动现金流出小计                              655,011,586.58        683,775,255.39
      经营活动产生的现金流量净额                       48,550,844.99        107,645,701.87
二、投资活动产生的现金流量:
  收回投资收到的现金
  取得投资收益收到的现金
  处置固定资产、无形资产和其他长期资
                                                           40,400.00                  240.00
产收回的现金净额
  处置子公司及其他营业单位收到的现
金净额
  收到其他与投资活动有关的现金
    投资活动现金流入小计                                  40,400.00                  240.00
  购建固定资产、无形资产和其他长期资
                                                       56,283,011.95        146,708,545.01
产支付的现金
  投资支付的现金                                      121,100,000.00
  取得子公司及其他营业单位支付的现
                                                       48,000,000.00
金净额
  支付其他与投资活动有关的现金
    投资活动现金流出小计                             225,383,011.95         146,708,545.01
      投资活动产生的现金流量净额                    -225,342,611.95        -146,708,305.01
三、筹资活动产生的现金流量:
  吸收投资收到的现金
  取得借款收到的现金                                  503,000,000.00        536,000,000.00
  收到其他与筹资活动有关的现金
    筹资活动现金流入小计                              503,000,000.00        536,000,000.00
  偿还债务支付的现金                                  438,000,000.00        501,195,693.98
  分配股利、利润或偿付利息支付的现金                    3,578,875.06          4,944,550.38
  支付其他与筹资活动有关的现金
    筹资活动现金流出小计                              441,578,875.06        506,140,244.36
      筹资活动产生的现金流量净额                       61,421,124.94         29,859,755.64
四、汇率变动对现金及现金等价物的影响
五、现金及现金等价物净增加额                        -115,370,642.02          -9,202,847.50
  加:期初现金及现金等价物余额                       177,630,964.85         164,310,146.60

                                            18 / 19
    江苏康缘药业股份有限公司 (股票代码:600557)                           2017 年第一季度报告



六、期末现金及现金等价物余额                          62,260,322.83           155,107,299.10



法定代表人:肖伟             主管会计工作负责人:尹洪刚               会计机构负责人:江锁成


4.2 审计报告

□适用 √不适用




                                            19 / 19